Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers

Trial Profile

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs AMY 101 (Primary) ; AMY 101 (Primary)
  • Indications Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Periodontitis; Renal failure
  • Focus Adverse reactions; First in man
  • Sponsors Amyndas Pharmaceuticals
  • Most Recent Events

    • 13 Dec 2017 Results published in the Amyndas Pharmaceuticals Media Release
    • 13 Dec 2017 Status changed from recruiting to completed, according to a Amyndas Pharmaceuticals media release.
    • 26 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top